Gene Regulation and Clinical Roles for Interferons in Neoplastic Diseases

Area of Science:

• Oncology
• Immunology
• Biotherapy

Background:

• Interferons (IFNs) represent a pioneering biological therapy for human malignancies.
• Clinical applications for IFNs in cancer treatment are expanding.
• IFNs have demonstrated efficacy in treating chronic myelogenous leukemia, hairy cell leukemia, follicular lymphomas, Kaposi's sarcoma, and melanoma.

Purpose of the Study:

• To review the expanding clinical indications and therapeutic applications of interferons (IFNs) in cancer treatment.
• To highlight the synergistic effects of IFNs when combined with other therapeutic modalities.
• To discuss the mechanisms by which IFNs modulate cellular function and gene expression for anti-cancer activity.

Main Methods:

• Review of international phase III clinical trials establishing therapeutic activity of IFNs.
• Analysis of preclinical and clinical data on combination therapies involving IFNs.
• Examination of IFN-mediated modulation of gene expression and immune responses.

Main Results:

• IFNs are approved for multiple cancers and show efficacy in treating viral infections that may predispose to cancer.
• IFNs synergize with surgery, chemotherapy, cytokines, and monoclonal antibodies to enhance tumor regression.
• IFN therapy improves prognosis, survival, and quality of life in specific cancer types, such as high-risk melanoma.

Conclusions:

• Interferons are versatile biotherapies with established roles in oncology.
• Combination therapy involving IFNs offers enhanced efficacy and improved patient outcomes.
• IFNs modulate gene expression and immune functions, supporting their use in diverse cancer treatment strategies.